Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Farmaceutica Remedia's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -36.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Farmaceutica Remedia's 3-Year ROIIC % or its related term are showing as below:
LTS:0M8I's 3-Year ROIIC % is ranked worse than 86.61% of 112
companies
in the Medical Distribution industry
Industry Median: 2.295
vs LTS:0M8I: -36.02
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Farmaceutica Remedia 3-Year ROIIC % Related Terms
Farmaceutica Remedia 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M8I vs MCK, COR, CAH: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's 3-Year ROIIC % falls into.
Farmaceutica Remedia's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 7.4037814 (Dec. 2025) - 5.880335 (Dec. 2022) )
/
( 53.768 (Dec. 2025) - 57.998 (Dec. 2022) )
=
1.5234464
/
-4.23
=
-36.02%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Farmaceutica Remedia (LTS:0M8I) has a 3-Year ROIIC % of -36.02 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Farmaceutica Remedia and its competitors. According to the industry distribution chart, Farmaceutica Remedia ranks #97 out of 112 companies in the Medical Distribution industry, placing it in the top 86.6%.
Is Farmaceutica Remedia's 3-Year ROIIC % too high?
Farmaceutica Remedia's current 3-Year ROIIC % is -36.02. Based on the distribution chart, Farmaceutica Remedia ranks #97 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's 3-Year ROIIC % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #97 out of 112 companies for 3-Year ROIIC %. This places Farmaceutica Remedia in the lower half of its industry. The industry median 3-Year ROIIC % is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.30, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current 3-Year ROIIC % is -36.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current 3-Year ROIIC % of -36.02. The stock's GF Value™ is lei0.22, compared to a current price of lei0.25 — trading 13.6% above its estimated fair value. The current 3-Year ROIIC % is -36.02. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current 3-Year ROIIC % is -36.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 13.6% above its estimated GF Value™ of lei0.22.
Key valuation signals for LTS:0M8I:
3-Year ROIIC %: -36.02
GF Value™: lei0.22 vs. price of lei0.25 (13.6% above fair value)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for LTS:0M8I
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
